Obezite Patogenezi

Obezite, vücutta aşırı yağ dokusunun birikmesiyle sonuçlanan, morbidite ve mortalite riskini artıran ve yaşam beklentisini belirgin bir şekilde azaltan karmaşık multifaktöryel bir hastalıktır. Obezite aşırı kalori alımı ve yetersiz kalori harcaması ile karakterizedir. Obezite bir hastalıktır. Suçlu hasta değil fizyoloji olabilir. Artan kanıtlar, obezitenin, sadece aşırı kiloda pasif birikimden ziyade, enerji denge sisteminin bir bozukluğu olduğunu düşün-dürmektedir. Sedanter yaşam tarzı ve diyet alışkanlıklarında değişiklikler, hipotalamus ve gastrointestinal hormonların enerji dengesi ile olan ilişkileri, çevresel etkenler, endokrin bozucular, genetik, intrauterin dönemdeki kötü metabolik koşullar, kullanılan ilaçlar başlıca nedenlerdir. Obezite patogenezi tam olarak aydınlatılmamıştır. Patogenezi aydınlatmaya yönelik çalışmalar yapılmalıdır. Diyet ve egzersizin ötesinde, kötü sos-yoekonomik durum ve çevresel faktörler endokrin bozucular ve sedanter yaşam tarzı obezite riskine yol açar.

Pathogenesis of Obesity

Obesity is a complex multifactorial disorder that increases the risk of morbidity and mortality, resulting in the accumulation of excess fat in the body, and significantly reduces life expectancy. Obesity is characterized by excessive calorie intake and inadequate calorie expenditure. Obesity is a disease. The Blame may be put on the physiology, but not on the patient. Increased evidence suggests that obesity is merely a disorder of the energy balance system, far from passive accumulation in excess. Changes in sedentary lifestyle and dietary habits, the association of hypothalamus and gastrointestinal hormones with energy balance, environmental factors, endocrine disruptors, genetics, poor metabolic conditions in intrauterine period, drugs used are the main reasons. Obesity pathogenesis is not fully understood. Studies to illuminate pathogenesis should be done. Beyond diet and exercise, bad environmental factors and socioeconomic status, endocrine disruptors and sedentary lifestyle lead to obesity risk.

PDF

___

World Health Organisation. Global Database on Body Mass Index 2016.
Rayner G, Lang T. Clinical Obesity in Adults and Children. Wiley-Blackwell; Malden, USA: Obesity: Using the ecologic public health app-roach to overcome policy cacophony; 2009; 452-70.
Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med 2017; 376:1492.
Hall KD, Guo J. Obesity energetics: body we-ight regulation and the effects of diet composi-tion. Gastroenterology 2017; 152:1718-27.
M. Andrew Greganti and Marschall S. Runge Obesity Netter's Internal Medicine E-Book. El-sevier Health Sciences 2008; 4: 18-28.
Rosenbaum M, Leibel RL, and Hirsch J: Obe-sity. N Engl J Med 1997; 337: 396-408.
Kelesidis T, Kelesidis I, Chou S, et al. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 2010; 152: 93-100.
Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5.
Wiedmer P, Nogueiras R, Broglio F, et al. Ghre-lin, obesity and diabetes. Nat Clin Pract Endoc-rinol Metab 2007; 3: 705-12.
Pratley RE: Gene-environment interactions in the pathogenesis of type 2 diabetes mellitus: les-sons learned from the Pima Indians. Proc Nutr Soc 1998; 57: 175-81.
Brown CL, Perrin EM. Obesity prevention and treatment in primary care. Acad Pediatr 2018; 2859: 308-5.
Marseglia L, Manti S, D'Angelo G,et al. Obesity and breastfeeding: The strength of association. Women Birth 2015; 28: 81-6.
Santangeli L, Sattar N, Huda SS. Impact of maternal obesity on perinatal and childhood outcomes. Best Pract Res Clin Obstet Gynaecol 2015; 29: 438-48.
Fall T, Mendelson M, Speliotes EK. "Recent advances in human genetics and epigenetics of adiposity: pathway to precision medicine?" Gastroenterology 2017; 152: 1695-706.
Huvenne H, Dubern B, Clément K, et al. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts 2016; 9: 158-73. doi: 10.1159/000445061.
Chung W.K. and Leibel R.L. Molecular physio-logy of syndromic obesities in humans. Trends Endocrinol Metab 2005; 16: 267-72.
Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest 2015; 38: 1249-63.
Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet 2013; 21: 8-13.
Nicolai JP, Lupiani JH, Wolf AJ. An integrative approach to Obesity. In I Rakel D. Integrative Medicine. 3rd Ed. Elsevier Saanders, Philadelp-hia, PA Chapter 38. p. 364-75
Bowles NP, Karatsoreos IN, Li X et al. A perip-heral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc Natl Acad Sci USA 2015; 112: 285-290.
Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approac-hes to treatment. Diabetes Care 2015; 38: 1161-72.
Welle S, Schwartz RG, Statt M, et al. Reduced metabolic rate during beta-adrenergic blockade in humans. Metabolism 1991; 40: 619-22.
Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsyc-hotics. Br J Psychiatry 1988; 153: 214–217.
Verhaegen AA, Van Gaal LF. Drug-induced obesity and its metabolic consequences: a re-view with a focus on mechanisms and possible therapeutic options. J Endocrinol Invest 2017; 40: 1165-74.

ISSN: 1300-9818
Başlangıç: 2015
Yayıncı: Fırat Üniversitesi Tıp Fakültesi

Arşiv